FY2026 Earnings Forecast for FDMT Issued By Leerink Partnrs

4D Molecular Therapeutics, Inc. (NASDAQ:FDMT - Free Report) - Stock analysts at Leerink Partnrs issued their FY2026 earnings per share (EPS) estimates for 4D Molecular Therapeutics in a note issued to investors on Wednesday, April 16th. Leerink Partnrs analyst M. Foroohar forecasts that the company will post earnings of ($3.82) per share for the year. The consensus estimate for 4D Molecular Therapeutics' current full-year earnings is ($2.84) per share.

4D Molecular Therapeutics (NASDAQ:FDMT - Get Free Report) last announced its quarterly earnings data on Friday, February 28th. The company reported ($0.90) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.10).

A number of other equities research analysts also recently weighed in on FDMT. Weiss Ratings restated a "sell (d-)" rating on shares of 4D Molecular Therapeutics in a research note on Tuesday, April 8th. Chardan Capital lowered their price target on shares of 4D Molecular Therapeutics from $30.00 to $28.00 and set a "buy" rating for the company in a report on Tuesday, March 4th. BMO Capital Markets lowered 4D Molecular Therapeutics from an "outperform" rating to a "market perform" rating and reduced their price objective for the stock from $40.00 to $15.00 in a research report on Monday, January 13th. Bank of America dropped their target price on 4D Molecular Therapeutics from $42.00 to $40.00 and set a "buy" rating for the company in a research report on Monday, March 10th. Finally, Royal Bank of Canada reduced their price target on 4D Molecular Therapeutics from $39.00 to $35.00 and set an "outperform" rating on the stock in a report on Monday, March 3rd. One investment analyst has rated the stock with a sell rating, two have given a hold rating and five have assigned a buy rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $26.71.

4D Molecular Therapeutics Price Performance

Shares of FDMT stock traded up $0.19 on Thursday, hitting $3.27. 210,290 shares of the company's stock were exchanged, compared to its average volume of 828,050. 4D Molecular Therapeutics has a 12 month low of $2.24 and a 12 month high of $28.93. The company has a 50 day moving average of $3.74 and a 200 day moving average of $5.78. The stock has a market cap of $151.18 million, a P/E ratio of -1.14 and a beta of 2.89.

Institutional Trading of 4D Molecular Therapeutics

A number of large investors have recently bought and sold shares of the business. Harbor Capital Advisors Inc. acquired a new position in 4D Molecular Therapeutics in the first quarter valued at approximately $99,000. Wellington Management Group LLP raised its stake in 4D Molecular Therapeutics by 6.7% during the 4th quarter. Wellington Management Group LLP now owns 177,279 shares of the company's stock worth $987,000 after buying an additional 11,089 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC grew its position in 4D Molecular Therapeutics by 7.1% in the 4th quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 44,324 shares of the company's stock valued at $247,000 after purchasing an additional 2,925 shares during the period. Velan Capital Investment Management LP bought a new stake in shares of 4D Molecular Therapeutics during the fourth quarter worth about $56,000. Finally, Two Sigma Advisers LP raised its stake in shares of 4D Molecular Therapeutics by 452.0% in the fourth quarter. Two Sigma Advisers LP now owns 126,400 shares of the company's stock worth $704,000 after purchasing an additional 103,500 shares during the last quarter. 99.27% of the stock is currently owned by institutional investors and hedge funds.

About 4D Molecular Therapeutics

4D Molecular Therapeutics, Inc, a clinical-stage biotherapeutics company, develops genetic medicines using its therapeutic vector evolution platform in the Netherland and the United States. The company develops a portfolio of genetic medicine product candidates focuses in three therapeutic areas for ophthalmology, cardiology, and pulmonology.